87 related articles for article (PubMed ID: 1329778)
1. Negative inotropic and chronotropic activity of calcium channel ligands possessing a xanthone 1,4-dihydropyridine backbone.
Chiarini A; Rampa A; Bisi A; Budriesi R; Valenti P
Arzneimittelforschung; 1992 Jun; 42(6):797-801. PubMed ID: 1329778
[TBL] [Abstract][Full Text] [Related]
2. Xanthone 1,4-dihydropyridine derivatives with a potent selective bradycardic effect.
Valenti P; Chiarini A; Gasperi F; Budriesi R
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):122-5. PubMed ID: 2334451
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of xanthone and fluorenone-1,4-dihydropyridine-5-phosphonates.
Budriesi R; Rampa A; Bisi A; Fabbri G; Chiarini A; Valenti P
Arzneimittelforschung; 1996 Apr; 46(4):374-7. PubMed ID: 8740081
[TBL] [Abstract][Full Text] [Related]
4. 4-heterotricyclic substituted 1,4-dihydropyridines with a potent selective bradycardic effect.
Rampa A; Chiarini A; Bisi A; Budriesi R; Valenti P
Arzneimittelforschung; 1991 Jul; 41(7):705-9. PubMed ID: 1772458
[TBL] [Abstract][Full Text] [Related]
5. SAR studies in the field of Ca-antagonists: 2-substituted 1,4-dihydropyridines with a xanthone backbone.
Bisi A; Budriesi R; Chiarini A; Rampa A; Valenti P
Farmaco; 1993 Nov; 48(11):1491-502. PubMed ID: 8110362
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological profile of some chloroxanthone-1, 4-dihydropyridine derivatives.
Bisi A; Budriesi R; Rampa A; Fabbri G; Chiarini A; Valenti P
Arzneimittelforschung; 1996 Sep; 46(9):848-51. PubMed ID: 8876931
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological characterization of some benzazepinone derivatives.
Budriesi R; Rampa A; Bisi A; Fabbri G; Chiarini A; Valenti P
Arzneimittelforschung; 1995 Mar; 45(3):234-9. PubMed ID: 7741775
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and cardiodepressant activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pentatomic-heteroaryl)-3,5-pyridine-dicarbo xylates. 2.
Baraldi PG; Garuti L; Leoni A; Cacciari B; Budriesi R; Chiarini A
Drug Des Discov; 1993; 10(4):319-29. PubMed ID: 8148471
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and cardiovascular properties of furazanyl-1,4-dihydropyridines and of furoxanyl analogues.
Gasco AM; Fruttero R; Sorba G; Gasco A; Budriesi R; Chiarini A
Arzneimittelforschung; 1992 Jul; 42(7):921-5. PubMed ID: 1418057
[TBL] [Abstract][Full Text] [Related]
10. PN 200-110, a new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta.
Hof RP; Scholtysik G; Loutzenhiser R; Vuorela HJ; Neumann P
J Cardiovasc Pharmacol; 1984; 6(3):399-406. PubMed ID: 6202964
[TBL] [Abstract][Full Text] [Related]
11. Fluorenone and benzophenone 1,4-dihydropyridine derivatives with cardiodepressant activity.
Rampa A; Budriesi R; Bisi A; Chiarini A; Valenti P
Arzneimittelforschung; 1992 Nov; 42(11):1284-7. PubMed ID: 1492840
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship studies in the field of calcium antagonists. Xanthone 1,4-dihydropyridines bearing a 2,3-lactone ring.
Rampa A; Budriesi R; Bisi A; Fabbri G; Barili PL; Chiarini A; Valenti P
Arzneimittelforschung; 1995 Sep; 45(9):957-62. PubMed ID: 7488312
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
14. Imidazo[2,1-b]thiazole system: a scaffold endowing dihydropyridines with selective cardiodepressant activity.
Budriesi R; Ioan P; Locatelli A; Cosconati S; Leoni A; Ugenti MP; Andreani A; Di Toro R; Bedini A; Spampinato S; Marinelli L; Novellino E; Chiarini A
J Med Chem; 2008 Mar; 51(6):1592-600. PubMed ID: 18303827
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
[TBL] [Abstract][Full Text] [Related]
16. Coumarin 1,4-dihydropyridine derivatives.
Valenti P; Rampa A; Budriesi R; Bisi A; Chiarini A
Bioorg Med Chem; 1998 Jun; 6(6):803-10. PubMed ID: 9681146
[TBL] [Abstract][Full Text] [Related]
17. PD 122860: a novel dihydropyridine with sodium channel stimulating and calcium channel blocking properties.
Haleen SJ; Steffen RP; Sircar I; Major TC; Taylor MD; Pugsley TA; Weishaar RE
J Pharmacol Exp Ther; 1989 Jul; 250(1):22-30. PubMed ID: 2473188
[TBL] [Abstract][Full Text] [Related]
18. The dihydropyridines modulate neurotensin inotropic action paradoxically.
Golba KS; Deja M; Imiołek P; Kotyla PJ; Biernat J; Woś S; Herman ZS
J Physiol Pharmacol; 1995 Dec; 46(4):419-27. PubMed ID: 8770786
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate.
Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R
Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and cardiovascular properties of fluorenyl derivatives related to verapamil.
Romanelli MN; Teodori E; Scapecchi S; Dei S; Budriesi R; Chiarini A
Farmaco; 1991 Oct; 46(10):1121-38. PubMed ID: 1815578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
